Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Deffered Revenue (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 55.51% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a 55.51% decrease, with the full-year FY2024 number at $3.3 million, down 45.64% from a year prior.
  • Non-Current Deffered Revenue was $1.8 million for Q3 2025 at Caribou Biosciences, down from $1.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $24.2 million in Q2 2021 to a low of $1.8 million in Q3 2025.
  • A 5-year average of $6.8 million and a median of $3.9 million in 2024 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 660.8% in 2022, then crashed 61.75% in 2023.
  • Caribou Biosciences' Non-Current Deffered Revenue stood at $2.1 million in 2021, then surged by 660.8% to $16.0 million in 2022, then plummeted by 61.75% to $6.1 million in 2023, then plummeted by 45.64% to $3.3 million in 2024, then crashed by 47.06% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Non-Current Deffered Revenue are $1.8 million (Q3 2025), $1.8 million (Q2 2025), and $2.6 million (Q1 2025).